Irlanda - anglès - HPRA (Health Products Regulatory Authority)

cipla europe nv - fluticasone propionate; salmeterol xinafoate - pressurised inhalation, suspension - 25/250 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

fannin limited - fluticasone propionate; salmeterol xinafoate - pressurised inhalation, suspension - 25/250 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

cipla europe nv - fluticasone propionate; salmeterol xinafoate - pressurised inhalation, suspension - 25/250 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

rowex ltd - azelastine hydrochloride; fluticasone propionate - nasal spray, suspension - fluticasone, combinations

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 8 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 40 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 20 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 500 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 100 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

Israel - anglès - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - powder for inhalation - fluticasone propionate 250 mcg - fluticasone - fluticasone - prophylactic management of all grades of asthma.fluticasone propionate is indicated for the management of copd when used in combination with long-acting bronchodilators (e.g. long-acting beta agonists (labas)).